Literature DB >> 12957197

Lower urinary tract symptoms/benign prostatic hyperplasia: minimizing morbidity caused by treatment.

Claude C Schulman1.   

Abstract

The beneficial effects of treatment for lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH), or LUTS/BPH, have to be balanced against the morbidity associated with treatment. Invasive surgery, such as transurethral resection of the prostate, has been associated with irreversible complications (eg, impotence and retrograde ejaculation). Alpha(1)-adrenoceptor antagonists provide effective and fast relief of LUTS/BPH. In contrast to finasteride, they are not associated with sexual dysfunction (eg, decreased libido or impotence). Alpha(1)-adrenoceptor antagonists induce adverse events associated with interference with blood pressure regulation. The alpha(1A)/alpha(1D)-adrenoceptor antagonist tamsulosin has the lowest potential to interfere with blood pressure regulation and induce related adverse events. In addition, tamsulosin seems to be as well tolerated as phytotherapy, except for a higher incidence of abnormal ejaculation. Abnormal ejaculation occurs in 4% to 11% of patients receiving a alpha(1)-adrenoceptor antagonist, which is, however, well tolerated; <1% of patients discontinue because of this adverse event. In placebo-controlled trials, abnormal ejaculation has been predominantly reported for tamsulosin, but in most direct comparative studies, the incidence was comparable to that of other alpha(1)-adrenoceptor antagonists. Men with LUTS/BPH have an increased risk of impaired sexual function. However, alpha(1)-adrenoceptor antagonists, such as tamsulosin, may slightly improve sexual dysfunction together with LUTS problems. Combination therapy of an alpha(1)-adrenoceptor antagonist and finasteride has a similar adverse-event profile as each monotherapy, except for an increased risk of abnormal ejaculation. The discontinuation rate because of adverse events does not seem to be higher than with monotherapy. Medical therapies, and particularly alpha(1)-adrenoceptor antagonists such as tamsulosin, can be considered a first-line treatment option for LUTS/BPH because they provide effective relief of bothersome LUTS with excellent tolerability.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12957197     DOI: 10.1016/s0090-4295(03)00471-0

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  11 in total

Review 1.  Novel drug targets for the pharmacotherapy of benign prostatic hyperplasia (BPH).

Authors:  S Ventura; V l Oliver; C W White; J H Xie; J M Haynes; B Exintaris
Journal:  Br J Pharmacol       Date:  2011-07       Impact factor: 8.739

Review 2.  Predictive medicine in non-malignant urological disorders.

Authors:  Mariangela Mancini; Antonio Cisternino; Ivan Matteo Tavolini; Fabrizio Dal Moro; Pierfrancesco Bassi
Journal:  World J Urol       Date:  2003-12-20       Impact factor: 4.226

Review 3.  Silodosin in the treatment of benign prostatic hyperplasia.

Authors:  Maxime Rossi; Thierry Roumeguère
Journal:  Drug Des Devel Ther       Date:  2010-10-27       Impact factor: 4.162

4.  Lack of awareness of erectile dysfunction in many men with risk factors for erectile dysfunction.

Authors:  Ridwan Shabsigh; Joel Kaufman; Michelle Magee; Dana Creanga; David Russell; Meeta Budhwani
Journal:  BMC Urol       Date:  2010-11-05       Impact factor: 2.264

Review 5.  Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.

Authors:  Jae Hung Jung; Jiye Kim; Roderick MacDonald; Balaji Reddy; Myung Ha Kim; Philipp Dahm
Journal:  Cochrane Database Syst Rev       Date:  2017-11-22

Review 6.  Safety and efficacy of silodosin for the treatment of benign prostatic hyperplasia.

Authors:  Masaki Yoshida; Junzo Kudoh; Yukio Homma; Kazuki Kawabe
Journal:  Clin Interv Aging       Date:  2011-06-22       Impact factor: 4.458

7.  Anti-proliferative effects of qianliening capsules on prostatic hyperplasia in vitro and in vivo.

Authors:  Xiaoyong Zhong; Jiumao Lin; Jianheng Zhou; Wei Xu; Zhenfeng Hong
Journal:  Mol Med Rep       Date:  2015-03-27       Impact factor: 2.952

8.  Clinical Background of Patients with Sperm in Their Urinary Sediment.

Authors:  Masuomi Tomita; Eiji Kikuchi; Takahiro Maeda; Yusuke Kabeya; Takeshi Katsuki; Yoichi Oikawa; Kiyoe Kato; Masakazu Ohashi; So Nakamura; Mototsugu Oya; Akira Shimada
Journal:  PLoS One       Date:  2015-09-11       Impact factor: 3.240

9.  Investigation of ejaculatory disorder by silodosin in the treatment of prostatic hyperplasia.

Authors:  Koichi Sakata; Tatsuo Morita
Journal:  BMC Urol       Date:  2012-10-19       Impact factor: 2.264

10.  Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia.

Authors:  Eu Chang Hwang; Shreyas Gandhi; Jae Hung Jung; Mari Imamura; Myung Ha Kim; Ran Pang; Philipp Dahm
Journal:  Cochrane Database Syst Rev       Date:  2018-10-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.